Cancer Pain Clinical Trial
Official title:
Observation of In-Hospital/ In-Home Continuous Monitoring of Human Physiology and Self-Reported Pain Score Among Patients With Moderate-to-severe Cancer Pain
To assess whether the patient's self-reported pain level is associated with a multivariate physiological biomarker bias achieved in the actual clinical setting. This study will use a clinical-grade wearable sensor to continuously monitor the patient's physiological condition (pain-related biomarkers) and use the mobile app to allow participants to actively report their pain scores, symptoms and quality of life.After analysis of the biomarkers we may predict the coming pain attacks by way of the meaningful biomarkers.
Subjective scores have traditionally been used to measure human pain, such as the visual
analog scale (VAS) to determine the presence or absence of pain and its severity. People can
only express the pain experienced by dictation, scale, and image depicting the degree of
pain. Although this is important information, the self-evaluation method has problems for
diagnosis and research purposes. The results of a person's self-assessment depend on past
pain experiences and many other cognitive and behavioral factors and therefore change over
time. In addition, it is difficult to obtain a reliable comparison between the rewards of
different people. When the patient complains of a certain degree of pain, it is impossible to
know whether it is equivalent to the same pain described by other patients. Moreover, it is
difficult to obtain self-evaluation results among ethnic groups of different natures, such as
young people, patients who block the transmission of ideas due to different disease types,
and those who are unconscious. A variety of survey-based pain scales and functions have been
developed recently, and the utility has improved.
However, because it is still based on self-assessment, it will leave some of the same
problems with self-assessment. Developmental measurements of biomarkers or surrogate markers
with acute and/or chronic pain have made significant progress over the past few years. Thanks
to the development of new and improved technologies, such as in the field of angiography and
wearable biosensors, there has been considerable development. Studies have shown that pupils
respond to a variety of different stimuli and may predict the presence of pain. There are
many different physiological parameters, such as changes in heart rate, pulsating components
of the heart cycle, and skin activity, which have been shown to be associated with the
presence or absence of pain. From the development of research in this field, it is feasible
to develop clinical tools for measuring the presence or absence of acute and/or chronic pain,
including cancer pain, using biomarkers or surrogate markers. This objective tool can make
more significant advances in clinical pain research and treatment.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03375515 -
PCA vs Non-PCA Intravenous Hydromorphone Titration for Severe Cancer Pain
|
Phase 3 | |
Recruiting |
NCT03431922 -
Endovascular Denervation in Patients With Cancer Pain
|
N/A | |
Not yet recruiting |
NCT05265052 -
3D1002 in Combination With Oxycodone Hydrochloride Sustained-release Tablets in Patients With Moderate to Severe Cancer Pain
|
Phase 2 | |
Withdrawn |
NCT05325164 -
Methadone for 'Adenocarcinopathic' Pain Treatment
|
Phase 3 | |
Completed |
NCT02664987 -
Analgesic Treatment for Cancer Pain in South East Asia
|
N/A | |
Completed |
NCT01946555 -
Prospective Longitudinal Observational Study to Evaluate the Clinical Characteristics and Opioids Treatments in Patients With Breakthrough Cancer Pain
|
N/A | |
Active, not recruiting |
NCT04095234 -
Integrative Medicine for Pain in Patients With Advanced Cancer Trial (IMPACT)
|
Phase 2 | |
Recruiting |
NCT05800834 -
Benefits of Morphine Gel for Pain Reduction in Patients With Cancer Wounds
|
Phase 2 | |
Recruiting |
NCT04907643 -
Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes
|
N/A | |
Completed |
NCT02609828 -
Phase 3 Study on the Efficacy and Safety of Tanezumab in Patients With Cancer Pain Due to Bone Metastasis Who Are Taking Background Opioid Therapy
|
Phase 3 | |
Completed |
NCT03331055 -
PENS or TENS for Pain in Pancreatic Cancer
|
N/A | |
Recruiting |
NCT05506878 -
Auriculo-Nerve Stimulation on Post-Operative Opioid Requirement
|
N/A | |
Completed |
NCT00766831 -
An Efficacy and Safety Study of Hydromorphone Oral Osmotic System (OROS) in Korean Participants With Cancer Pain
|
Phase 4 | |
Recruiting |
NCT05051735 -
PARASTOP - Paracetamol With Strong Opioids
|
Phase 3 | |
Not yet recruiting |
NCT05348174 -
Randomized Controlled Trial of Virtual Reality Assisted Guided Imagery (VRAGI) for Pain in Advanced Cancer Patients.
|
N/A | |
Completed |
NCT05209906 -
An Observation Study to Assess the Efficacy and Safety of Proportional Doses of Painkyl® in Patients With Breakthrough Cancer Pain
|
||
Completed |
NCT03031938 -
Protocol to Monitor the Neurological Development of Infants With Exposure in Utero From Birth to 15 Months in Tanezumab Clinical Studies
|
Phase 3 | |
Not yet recruiting |
NCT05594459 -
Early Treatment With Invasive Technique in Cancer Pain Management
|
N/A | |
Withdrawn |
NCT04666623 -
Compare the Efficacy and Safety of Intranasal Esketamine in Chronic Opioid Refractory Pain
|
Phase 2 | |
Not yet recruiting |
NCT05049811 -
Effects of Mobile Medicine on Cancer Patients
|
N/A |